Immutep - Public Comps and Valuation Multiples

Immutep Overview

About Immutep

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3’s ability to stimulate the body’s immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Founded

1987

HQ

Employees

Website

immutep.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $3.6M

LTM EBITDA -$43.8M

EV

$208M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Immutep Financials

As of September 2025, Immutep reported last 12-month revenue of $3.6M and EBITDA of -$43.8M.

In the same period, Immutep achieved -$43.5M in LTM net income.

See Immutep valuation multiples based on analyst estimates

Immutep P&L

In the most recent fiscal year, Immutep reported EBITDA of -$27.8M.

Immutep expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Immutep valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$3.6M	XXX	n/a	XXX	XXX	XXX
Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
Gross Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA	-$43.8M	XXX	-$27.8M	XXX	XXX	XXX
EBITDA Margin	-1222%	XXX	n/a	XXX	XXX	XXX
EBIT	-$44.1M	XXX	-$30.3M	XXX	XXX	XXX
EBIT Margin	-1232%	XXX	n/a	XXX	XXX	XXX
Net Profit	-$43.5M	XXX	-$27.8M	XXX	XXX	XXX
Net Margin	-1216%	XXX	n/a	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Immutep including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $3.6M. EBITDA for the last twelve months was -$43.8M.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$3.6M	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$43.8M	Analyst estimates available to subscribers	-$27.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	-1222.5% EBITDA margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$44.1M	Analyst estimates available to subscribers	-$30.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-1231.5% EBIT margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$43.5M	Analyst estimates available to subscribers	-$27.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-1215.7% net profit margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Immutep

This financial data table provides comprehensive performance metrics for Immutep, a company based in Australia. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Immutep generated $3.6M in revenue over the last twelve months.
The company achieved -$43.8M in EBITDA over the last twelve months.
Net income over the last twelve months reached -$43.5M.

Fiscal Year Performance

Fiscal year EBITDA was -$27.8M.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Immutep. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Immutep Stock Performance

Immutep has current market cap of AUD 448M (or $291M), and EV of AUD 320M (or $208M).

Market Cap Evolution

Immutep Stock Data

As of October 23, 2025, Immutep's stock price is AUD 0 (or $0).

See Immutep trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$208M	$291M	XXX	XXX	XXX	XXX	$-0.03

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Immutep Valuation Multiples

Immutep's trades at n/a EV/Revenue multiple, and -7.7x EV/EBITDA.

See valuation multiples for Immutep and 15K+ public comps

Immutep Financial Valuation Multiples

As of October 23, 2025, Immutep has market cap of $291M and EV of $208M.

Equity research analysts estimate Immutep's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Immutep has a P/E ratio of -6.7x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$291M	XXX	$291M	XXX	XXX	XXX
EV (current)	$208M	XXX	$208M	XXX	XXX	XXX
EV/Revenue	58.0x	XXX	n/a	XXX	XXX	XXX
EV/EBITDA	-4.7x	XXX	-7.7x	XXX	XXX	XXX
EV/EBIT	-4.7x	XXX	-7.3x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	-6.7x	XXX	-10.8x	XXX	XXX	XXX
EV/FCF	-4.7x	XXX	-9.0x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Immutep Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Immutep Margins & Growth Rates

Immutep's last 12 month revenue growth is 9%

Immutep's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.7M for the same period.

Immutep's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Immutep's rule of X is -1201% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Immutep and other 15K+ public comps

Immutep Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	9%	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	-1222%	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	21%	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	-1201%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.7M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	n/a	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial